A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
INCB 00928-104
Phase 2 other active
Quick answer
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders for Anaemia associated with myelofibrosis is a Phase 2 program (other) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Incyte Biosciences Distribution B.V.
- Indication
- Anaemia associated with myelofibrosis
- Phase
- Phase 2
- Modality
- other
- Status
- active